PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of plasmacytoid dendritic cells.
PDC*line Pharma has raised $13.3M in total funding. The most recent round was Series B. The last funding was announced in December 2021.
PDC*line Pharma's investors include Korea Investment Partners, Sambrinvest, Meusinvest (Noshaq), S.R.I.W., UTC Investment Co..
PDC*line Pharma is headquartered in La Tronche, France.
PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of plasmacytoid dendritic cells.
PDC*line Pharma is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PDC*line Pharma — Funding & Investors." VCBacked, December 6, 2021, https://www.vcbacked.co/company/pdcline-pharma. Accessed August 14, 2026.
VCBacked. (2021). PDC*line Pharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/pdcline-pharma
{{cite web |title=PDC*line Pharma — Funding & Investors |url=https://www.vcbacked.co/company/pdcline-pharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated